Financials Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
733.04 ^USD	-1.20%		-4.55%	-5.03%

16/01	Where the Money's Moving
16/01	Bayer's Eylea Secures EU Approval for Retinal Vein Occlusion	MT

Projected Income Statement: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	8,497	16,072	12,173	13,117	14,202	14,214	15,332	16,774
Change	-	89.14%	-24.26%	7.76%	8.27%	0.08%	7.86%	9.41%
EBITDA ¹	4,244	9,835	6,060	5,547	5,695	5,599	6,004	7,138
Change	-	131.7%	-38.38%	-8.47%	2.67%	-1.7%	7.25%	18.87%
EBIT ¹	3,577	8,947	5,719	5,126	5,212	4,683	5,197	6,356
Change	-	150.15%	-36.08%	-10.37%	1.69%	-10.16%	10.98%	22.29%
Interest Paid ¹	-56.9	-57.3	-59.4	-73	-55.2	-45.03	-57.15	-57.15
Earnings before Tax (EBT) ¹	3,810	9,326	4,859	4,199	4,780	5,146	4,613	5,433
Change	-	144.75%	-47.9%	-13.57%	13.83%	7.67%	-10.37%	17.78%
Net income ¹	3,513	8,075	4,338	3,954	4,413	4,316	4,192	4,981
Change	-	129.86%	-46.28%	-8.87%	11.61%	-2.19%	-2.86%	18.81%
Announcement Date	05/02/21	04/02/22	03/02/23	02/02/24	04/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	2,423	2,529	5,138	3,453	4,952	2,965	2,857	2,936	3,414	3,162	3,158	3,363	3,434	3,145	3,547	3,721	3,789	3,029	3,676	3,754	3,754	3,451	3,744	3,983	4,192
Change	-	4.37%	103.21%	-32.81%	43.41%	-40.12%	-3.64%	2.76%	16.29%	-7.39%	-0.13%	6.48%	2.13%	-8.42%	12.79%	4.89%	1.84%	-20.07%	21.36%	2.14%	-0.01%	-8.07%	8.5%	6.36%	5.27%
EBITDA ¹	1,229	1,311	3,564	2,057	2,903	1,558	1,344	1,488	1,637	1,315	1,351	1,488	1,395	1,157	1,469	1,581	1,488	1,004	1,499	1,459	1,718	1,491	1,713	2,002	1,726
Change	-	6.7%	171.84%	-42.27%	41.09%	-46.33%	-13.71%	10.67%	10.04%	-19.69%	2.77%	10.13%	-6.23%	-17.06%	26.96%	7.63%	-5.88%	-32.55%	49.3%	-2.64%	17.75%	-13.21%	14.89%	16.87%	-13.8%
EBIT ¹	1,167	1,113	3,347	1,847	2,640	1,483	1,285	1,413	1,537	1,215	1,248	1,382	1,282	1,043	1,348	1,459	1,362	876.9	1,364	1,322	1,108	1,061	1,269	1,372	1,394
Change	-	-4.65%	200.82%	-44.81%	42.9%	-43.8%	-13.35%	9.93%	8.78%	-20.95%	2.7%	10.78%	-7.26%	-18.65%	29.27%	8.24%	-6.69%	-35.61%	55.5%	-3.01%	-16.19%	-4.31%	19.62%	8.12%	1.61%
Charge d'intérêts ¹	-14.8	-14.6	-14.4	-14.2	-14.1	-13.6	-13.1	-15.3	-17.4	-18	-18.9	-17.8	-18.3	-16.1	-14.8	-13.8	-10.5	-8.7	-3.6	-19.3	-13.43	-12.5	-12.5	-12.5	-12.5
Earnings before Tax (EBT) ¹	1,225	1,253	3,753	1,817	2,503	1,061	963.2	1,510	1,325	858	1,083	1,111	1,148	700.7	1,628	1,493	958.1	905	1,519	1,763	825.8	-	-	-	-
Change	-	2.32%	199.51%	-51.59%	37.81%	-57.61%	-9.23%	56.75%	-12.26%	-35.23%	26.21%	2.58%	3.31%	-38.94%	132.35%	-8.3%	-35.83%	-5.54%	67.81%	16.11%	-53.17%	-	-	-	-
Net income ¹	1,149	1,115	3,099	1,632	2,229	973.5	852.1	1,316	1,197	817.8	968.4	1,008	1,160	722	1,432	1,341	917.7	808.7	1,392	1,460	586.7	847.5	1,009	1,137	1,300
Change	-	-2.96%	177.88%	-47.33%	36.56%	-56.33%	-12.47%	54.41%	-9.01%	-31.68%	18.42%	4.07%	15.06%	-37.74%	98.38%	-6.4%	-31.55%	-11.88%	72.08%	4.92%	-59.81%	44.45%	19.06%	12.69%	14.29%
Announcement Date	05/02/21	06/05/21	05/08/21	04/11/21	04/02/22	04/05/22	03/08/22	03/11/22	03/02/23	04/05/23	03/08/23	02/11/23	02/02/24	02/05/24	01/08/24	31/10/24	04/02/25	29/04/25	01/08/25	28/10/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-891	-9,833	-	-8,862	-6,308	-6,523	-8,357	-9,921
Change	-	-1,003.59%	-	-	28.82%	-3.41%	-28.12%	-18.71%
Announcement Date	05/02/21	04/02/22	03/02/23	02/02/24	04/02/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	614.6	551.9	590.1	718.6	755.9	869.6	918.7	882.9
Change	-	-10.2%	6.92%	21.78%	5.19%	15.04%	5.64%	-3.89%
Free Cash Flow (FCF) ¹	2,004	6,529	4,425	3,875	3,665	5,059	4,486	5,110
Change	-	225.9%	-32.23%	-12.42%	-5.44%	38.04%	-11.33%	13.91%
Announcement Date	05/02/21	04/02/22	03/02/23	02/02/24	04/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	49.95%	61.19%	49.79%	42.29%	40.1%	39.39%	39.16%	42.55%
EBIT Margin (%)	42.09%	55.67%	46.98%	39.08%	36.7%	32.95%	33.9%	37.89%
EBT Margin (%)	44.84%	58.03%	39.91%	32.01%	33.66%	36.21%	30.09%	32.39%
Net margin (%)	41.35%	50.25%	35.64%	30.14%	31.07%	30.36%	27.34%	29.69%
FCF margin (%)	23.58%	40.63%	36.35%	29.54%	25.8%	35.59%	29.26%	30.46%
FCF / Net Income (%)	57.03%	80.86%	101.99%	98.02%	83.05%	117.21%	107%	102.59%
Profitability
ROA	21.98%	37.91%	18.9%	16.2%	15.02%	11.41%	9.97%	10.6%
ROE	33.16%	54.21%	24.93%	20.74%	19.23%	15.38%	14.2%	14.99%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	7.23%	3.43%	4.85%	5.48%	5.32%	6.12%	5.99%	5.26%
CAPEX / EBITDA (%)	14.48%	5.61%	9.74%	12.95%	13.27%	15.53%	15.3%	12.37%
CAPEX / FCF (%)	30.68%	8.45%	13.34%	18.54%	20.63%	17.19%	20.48%	17.28%
Items per share
Cash flow per share ¹	22.75	63.11	44.18	40.4	38.41	62.77	51.14	52.12
Change	-	177.47%	-29.99%	-8.55%	-4.95%	63.43%	-18.53%	1.93%
Dividend per Share ¹	-	-	-	-	-	3.672	3.906	4.471
Change	-	-	-	-	-	-	6.37%	14.47%
Book Value Per Share ¹	102.5	177.6	211.6	241.4	272	310.5	344.9	388.3
Change	-	73.29%	19.18%	14.07%	12.7%	14.15%	11.06%	12.6%
EPS ¹	30.52	71.97	38.22	34.77	38.34	40.84	39.56	48.03
Change	-	135.81%	-46.89%	-9.03%	10.27%	6.53%	-3.15%	21.42%
Nbr of stocks (in thousands)	1,05,544	1,04,556	1,06,802	1,06,347	1,07,590	1,02,599	1,02,599	1,02,599
Announcement Date	05/02/21	04/02/22	03/02/23	02/02/24	04/02/25	-	-	-